Catalog No.
DHJ88801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
ANG-5, Angiopoietin-like protein 3, ANGPT5, Angiopoietin-5, ANGPTL3, Angiopoietin-related protein 3
Concentration
1.35 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y5C1
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN 1500, CAS: 1446419-85-7
Clone ID
Evinacumab
Evinacumab for Homozygous Familial Hypercholesterolemia, PMID: 32813947
Evinacumab in Patients with Refractory Hypercholesterolemia, PMID: 33196153
Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity, PMID: 31578082
Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?, PMID: 33295805
Antibodies to watch in 2020, PMID: 31847708
Evinacumab, PMID: 34292698
Evinacumab: First Approval, PMID: 34003472
Evinacumab-dgnb, PMID: 33881136
Lipid-Lowering Agents, PMID: 30702996
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia, PMID: 31242752
Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice, PMID: 31843957
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia, PMID: 28723334
Cholesterol Lowering Drugs, PMID: 27809434
A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects, PMID: 33130482
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease, PMID: 28538136
Novel emerging therapies in atherosclerosis targeting lipid metabolism, PMID: 32363959
Evinacumab for treatment of familial hypercholesterolemia, PMID: 34253139
Evinacumab for Homozygous Familial Hypercholesterolemia, PMID: 33567206
Evinacumab for Homozygous Familial Hypercholesterolemia, PMID: 33567205
[Evinacumab in patients with treatment-refractory hypercholesterolemia], PMID: 34014366
Evinacumab for Homozygous Familial Hypercholesterolemia, PMID: 33567207
Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia, PMID: 33976097
Evinacumab for Homozygous Familial Hypercholesterolemia. Reply, PMID: 33567208
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia, PMID: 32511037
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality, PMID: 32492513
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia, PMID: 31931117
The efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis, PMID: 34117182
Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects, PMID: 30011918
Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session, PMID: 32556778
Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy, PMID: 32753844
[Familial chylomicronemia], PMID: 32841138
Factoring in ANGPTL3 When LDL Is Refractory, PMID: 33296565
Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag, PMID: 34152800
Bypassing the LDL Receptor in Familial Hypercholesterolemia, PMID: 32813955
A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab, PMID: 34327869
ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report, PMID: 33691480
Emerging lipid lowering agents targeting LDL cholesterol, PMID: 32243228
Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia, PMID: 34238441
Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia, PMID: 33016816
ANGPTL3 inhibition lowers LDL-C levels in FH, PMID: 32855535
Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment, PMID: 31008773
Homozygous familial hypercholesterolemia: what treatments are on the horizon?, PMID: 32332430
Biotechnology Approaches for the Treatment of Dyslipidemia, PMID: 32519066
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data, PMID: 31100030
Novel therapies for familial hypercholesterolemia, PMID: 33278127
Evidence for improved survival with treatment of homozygous familial hypercholesterolemia, PMID: 32520777
Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders, PMID: 31856617
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy, PMID: 30403015
Marked plaque regression in homozygous familial hypercholesterolemia, PMID: 34004483
Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia, PMID: 33470417
For research use only. Not for human or drug use.
